Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immune 'Power Meter' could flag pneumonia relapses in ventilated patients

NCT ID NCT06607055

Knowledge-focused Sponsor: Centre Hospitalier Intercommunal Aix-Pertuis Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 26, 2026 · Last updated Aug 27, 2026 · Updated 1 time

Summary

This observational study looks at whether a blood marker called HLA-DR, which reflects immune function, can predict the return of ventilator-associated pneumonia in intensive care patients. Researchers will take weekly blood samples from 40 adults on mechanical ventilation with pneumonia to track immune suppression and see if it correlates with pneumonia recurrence, death, or viral reactivation. The goal is to better understand how immune status affects recovery in critically ill patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Blood collection for HLA-DR measurement
What this could lead to
If a link is found, doctors might use HLA-DR levels to predict which ICU patients are at higher risk of repeat pneumonia, guiding closer monitoring or preventive care.
What could go wrong
This is a small observational study, so it can only show associations, not cause and effect. Results may not apply to all ICU patients, and the immune marker might not reliably predict outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patient admitted in the ICU of the CHIAP under mechanical ventilation and with infectious pneumonia

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient over 18 years old * Patient admitted in the Intensive Care Unit of the CHIAP * Patient under mechanical ventilation * Patient with infectious pneumonia * Informed Consent Form (ICF) obtained from the patient or emergency ICF obtained from close relatives * Patient beneficiary of French social security, whatever the regime Exclusion Criteria: * Patient under 18 years old * Patient with severe neutropenia (neutrophils \< 0.5 G/L) * Patient under immunosuppressive treatment * Use of corticosteroids (intravenous or oral) prior to ICU admission * Use of therapeutic antibodies * Onco-hematological disease (e.g. lymphoma, leukemia...) under treatment or treated in the 5 years prior to inclusion * End of chemotherapy 6 months prior to inclusion * Patients with innate or acquired immune deficiency (e.g., severe combined immunodeficiency, HIV or AIDS, at any stage) * Patients with a decision to limit or discontinue active therapies, at the time of inclusion * Patients with an estimated ICU stay of less than 48 hours * Participation in an interventional study * Patient deprived of their liberty * Patient under tutorship or curatorship * Pregnant or breastfeeding woman

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pneumonia, ventilator-associated are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Pneumonia, Ventilator-Associated

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pneumonia, ventilator-associated

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Hospitalier Intercommunal Aix-Pertuis

    RECRUITING

    Aix-en-Provence, 13100, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.